Literature DB >> 10468868

Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation.

R L Comenzo1, J Wally, G Kica, J Murray, T Ericsson, M Skinner, Y Zhang.   

Abstract

AL (primary or immunoglobulin light chain) amyloidosis (AL) differs from myeloma per se in that tissue deposits of amyloid are found, typically in association with small numbers of clonal plasma cells producing lambda light chains, and also in that AL patients typically present with a predominantly dysfunctional organ-system. This constellation of features - fibrillar deposits comprised of light chains, lambda light chain predominance, and organ-system tropism and dysfunction - remains unexplained. Select patients with AL respond to haemopoietic stem cell transplantation (SCT) with clinical improvement and extended survival, particularly those who do not have cardiac involvement. In order to ascertain whether the organ-system tropism of AL was associated with immunoglublin light chain variable region (Ig VL) germline gene utilization, we attempted to clone, sequence and assign germline donors to the clonal Ig VL genes of 62 AL patients, all of whom were treated with SCT. We succeeded in 39 cases, identifying clonal AL genes derived from donors of the lambdaI (n = 10), lambdaII (n = 5), lambdaIII (n = 6), lambdaVI (n = 11) and KI (n = 7) subtypes. The majority of the donors (IGLV6S1, DPL5, DPL2, DPL23 and LFVK431) were genes that appear in the expressed repertoire <5% of the time, suggesting an intrinsic propensity to form amyloid under certain conditions. Patients whose clones derived from the lambdaVI IGLV6S1 donor uniformly presented with dominant renal involvement while those with other Vlambda or unknown donors often had dominant cardiac or other organ involvement, particularly patients whose clones derived from the lambdaI DPL2 donor. In addition, both early (<3 months) and overall post-SCT survival were significantly better in lambdaVI IGLV6S1 patients compared to patients with other Vlambda donors. These findings indicate that there are important associations in AL amyloidosis among Ig VL gene utilization, organ-system tropism and post-SCT survival.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468868     DOI: 10.1046/j.1365-2141.1999.01591.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL).

Authors:  Roshini S Abraham; Susan M Geyer; Marina Ramírez-Alvarado; Tammy L Price-Troska; Morie A Gertz; Rafael Fonseca
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

2.  Structural insights into the role of mutations in amyloidogenesis.

Authors:  Elizabeth M Baden; Edward G Randles; Awo K Aboagye; James R Thompson; Marina Ramirez-Alvarado
Journal:  J Biol Chem       Date:  2008-09-02       Impact factor: 5.157

Review 3.  Amyloidosis: pathogenesis and new therapeutic options.

Authors:  Giampaolo Merlini; David C Seldin; Morie A Gertz
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

4.  Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosis (Al).

Authors:  Diego Bellavia; Roshini S Abraham; Patricia A Pellikka; Angela Dispenzieri; John C Burnett; Ghormallah B Al-Zahrani; Tammy D Green; Michelle K Manske; Morie A Gertz; Fletcher A Miller; Theodore P Abraham
Journal:  J Am Soc Echocardiogr       Date:  2011-02-18       Impact factor: 5.251

Review 5.  Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.

Authors:  Mathew S Maurer; Perry Elliott; Raymond Comenzo; Marc Semigran; Claudio Rapezzi
Journal:  Circulation       Date:  2017-04-04       Impact factor: 29.690

6.  The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain.

Authors:  Elena S Klimtchuk; Olga Gursky; Rupesh S Patel; Kathryn L Laporte; Lawreen H Connors; Martha Skinner; David C Seldin
Journal:  Biochemistry       Date:  2010-10-20       Impact factor: 3.162

7.  AL-Base: a visual platform analysis tool for the study of amyloidogenic immunoglobulin light chain sequences.

Authors:  Kip Bodi; Tatiana Prokaeva; Brian Spencer; Maurya Eberhard; Lawreen H Connors; David C Seldin
Journal:  Amyloid       Date:  2009-03       Impact factor: 7.141

8.  Structural alterations within native amyloidogenic immunoglobulin light chains.

Authors:  Edward G Randles; James R Thompson; Douglas J Martin; Marina Ramirez-Alvarado
Journal:  J Mol Biol       Date:  2009-04-08       Impact factor: 5.469

9.  siRNA targeting the κ light chain constant region: preclinical testing of an approach to nonfibrillar and fibrillar light chain deposition diseases.

Authors:  X Ma; P Zhou; S W Wong; M Warner; C Chaulagain; R L Comenzo
Journal:  Gene Ther       Date:  2016-06-20       Impact factor: 5.250

10.  Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.

Authors:  Tanya L Poshusta; Laura A Sikkink; Nelson Leung; Raynell J Clark; Angela Dispenzieri; Marina Ramirez-Alvarado
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.